Nov 01,2023 TOP STORY

Cancer Center Researchers Seek to Harness Wearable Devices to Tailor Medical Treatments

A team of UVA Health researchers has demonstrated the potential of wearable and mobile devices such as smartwatches and smartphones to help doctors tailor treatments to the needs of individual patients. The scientists found that they could use wearable devices to predict patients’ levels of cortisol, the insomnia and stress hormone. Results from their laboratory experiments suggest that patients with pancreatic cancer who have high cortisol levels from disrupted sleep will experience faster growth of their tumors; that suggests that doctors could leverage this information from patients’ mobile devices to help at- risk patients keep their cortisol levels down and, in turn, slow their tumor growth. While the work is still in the early stages, the UVA scientists say their efforts demonstrate the tremendous potential of “mobile sensing” for improving and individualizing cancer care.

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Nov 06,2023

Can Collaborative Partnerships with Industry Drive Much-Needed Improvements in Lung Cancer Outcomes in the UK?

Lung cancer is the leading cause of cancer-related deaths in the UK, with 35,000 fatalities annually, posing a significant healthcare challenge in terms of costs and patient care. The introduction of advanced technology presents an opportunity to revolutionize patient pathways for quicker access to diagnostics and treatment. To address these issues, AstraZeneca's initiative, PATHFINDER, aims to optimize lung cancer pathways, aligning with NHS goals for timely diagnoses and treatment. It utilizes collaborations with experts and cutting-edge technology to streamline pathways, accelerate diagnoses, and increase curative treatment rates. Partners like IQVIA, Qure.ai, and Clinithink aid in auditing hospital sites, using AI solutions to process vast medical records swiftly and develop predictive models for early risk identification. This short interview with Vicky Heaton, Lung Cancer Franchise Head at AstraZeneca and Dr. Neal Navani, Consultant Respiratory Physician at University College London Hospitals, discuss the potential of the PATHFINDER initiative in identifying issues within the lung cancer pathway.

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Nov 01,2023

OncoHost to present proteomics-based predictive biomarker for immune-related adverse events in NSCLC Patients at SITC 2023

OncoHost has developed a novel computational model for predicting significant immune-related adverse events (irAEs) in patients with non-small cell lung cancer (NSCLC) based on proteomic profiling of pre-treatment blood samples. The study was conducted using OncoHost’s PROphet platform and will be presented as a poster at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting held between Nov. 1–Nov. 5, 2023, San Diego, CA and virtual.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 02,2023

Bristol Myers Squibb’s First Disclosures and New Data at ASH 2023 Highlight Company’s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across its hematology and cell therapy portfolio and pipeline at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place in San Diego, California from December 9 to 12, 2023. Results from 73 data disclosures across company-sponsored studies will be featured, including 22 oral presentations, showcasing BMS’ commitment to delivering transformative medicines that help more patients living with blood disorders.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 02,2023

Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting

Incyte announced that more than 40 abstracts highlighting data from eight of its hematology and oncology products will be presented at the upcoming 65th American Society of Hematology Annual Meeting 2023 (ASH 2023), held December 9-12, 2023, in San Diego and virtually. Sixteen oral presentations, as well as a plenary session and poster presentations, highlight new advances across eight of the Company’s medicines. Plenary Scientific Session will feature the full data from AGAVE-201 evaluating axatilimab, an anti-CSFR-1R monoclonal antibody, in patients with chronic graft-versus-host disease (GVHD).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 03,2023 TOP STORY

Aidence, Incepto, and Thirona launch joint clinical solution to support the expansion of lung cancer screening in Europe

MedTech companies Aidence, Incepto, and Thirona jointly introduce a comprehensive AI-powered software package for lung cancer screening and the analysis of emphysema. The companies aim to support healthcare providers in accelerating lung cancer screening roll-out across Europe with a suite of integrated artificial intelligence (AI) solutions and reporting capabilities that are seamlessly integrated in the radiology workflow. Netherlands-based Aidence and Thirona provide leading AI clinical applications for lung disease detection and management on chest CT scans. Aidence’s Veye Lung Nodules automatically detects, measures, classifies, and tracks the volume growth of pulmonary nodules, possible early signs of lung cancer. Thirona is specialized in advanced analysis of thoracic CT images providing high-precision quantification of anatomical lung structures for a wide range of diseases and pathologies.

COLLABORATION PARTNERSHIP

#product & service

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Nov 03,2023

Tempus Announces New ctDNA Assay, xF Monitor

Tempus, a leader in artificial intelligence and precision medicine, today announced xF Monitor – a new circulating tumor DNA (ctDNA) assay for research use only, which detects and monitors changes in circulating tumor fraction to determine early response to immunotherapy for patients with advanced cancers. The Tempus team will debut the xF Monitor assay at the Society for Immunotherapy of Cancer’s 38th Annual Meeting this week.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 03,2023

Q&A: The status of the White House-led CancerX initiative

Earlier this year, as part of the Moonshot, the Department of Health and Human Services launched CancerX, a public-private partnership effort to boost cancer innovation in the U.S. The Digital Medicine Society (DiMe) and Moffitt Cancer Center co-host CancerX, and Jennifer Goldsack, CEO of DiMe, sat down with MobiHealthNews to discuss the current state of the initiative. Goldsack mentioned that next week, they are going to have a readout on the first set of resources from the project focused on using digital technologies to address financial toxicity and issues around equity in cancer care and research. Together with the 150 member organizations in the CancerX community, Goldsack also added that they are thinking around defining a new care model that combines clinical decision support with virtual first care approaches. So, augmented telehealth and digitally-enabled navigation in order to reimagine the way that we care for someone following a cancer diagnosis. Currently, they are working with the project team on scope for this.

#rwd

#virtual care

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Nov 02,2023 TOP STORY

Roche partners with Ibex and AWS for cancer diagnosis support tools

Ibex's AI algorithms help clinicians in the diagnosis of breast and prostate biopsies and provide efficient, accurate and timely cancer diagnosis, support case prioritisation, determine the cancer grading and subtype, and identify important non-cancerous features. All diagnosis information is displayed seamlessly in Roche's navify Digital Pathology solution. Michael Rivers, lifecycle leader for Roche Digital Pathology, said: "This exciting collaboration brings powerful AI solutions to pathology labs. Using the navify Digital Pathology platform pathologists can securely access third-party AI-powered technology alongside Roche's growing menu of AI-based image analysis tools in an efficient clinical workflow." The Ibex algorithms are used at laboratories and hospitals worldwide, and help clinicians improve patient care as demonstrated by multiple clinical studies performed in the United States and Europe. These algorithms are currently for Research Use Only, not for use in diagnostic procedures, in the United States, and CE-marked for IVD use in Europe for breast and prostate cancer detection in multiple workflows.

COLLABORATION PARTNERSHIP

#product & service

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Nov 01,2023 TOP STORY

IMVARIA Enters into Know-how Agreement with Mayo Clinic to Improve the Understanding of Cancer through AI Digital Biomarkers

IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, announced a collaboration through a know-how agreement with Mayo Clinic to develop AI designed to significantly improve the analysis and understanding of cancer, beginning with lung cancer. With its unique platform, IMVARIA’s team of experts specializes in developing and advancing digital biomarkers to enable better patient outcomes. The collaboration brings together IMVARIA’s engineering expertise in digital biomarkers with Mayo Clinic’s know-how and data assets as part of the Validate pillar of Mayo Clinic Platform. The large-scale datasets will allow for comprehensive and reliable training of AI “brains” to discover and validate clinically relevant software-only biomarkers for cancer, analyzing complex text, numeric values, and images.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

#digital biomarkers

View Analyst & Ambassador Comments
Go to original news